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ABSTRACT
An increased understanding of the biology of colorectal cancer (CRC) has fuelled 
identification of biomarkers with potential to drive a stratified precision medicine care 
approach in this common malignancy.
We conducted a systematic review of health economic assessments of molecular 
biomarkers (MBMs) and their employment in patient stratification in CRC. Our 
analysis revealed scenarios where health economic analyses have been applied to 
evaluate the cost effectiveness of MBM-guided clinical interventions: (i) evaluation 
of Dihydropyrimidine dehydrogenase gene (DPYD) status to identify patients 
susceptible to 5-Fluouracil toxicity; (ii) determination of Uridine 5′-diphospho- 
glucuronosyltransferase family 1 member A1 gene (UGT1A1) polymorphism status 
to help guide irinotecan treatment; (iii) assessment of RAS/RAF mutational status 
to stratify patients for chemotherapy or Epidermal Growth Factor Receptor (EGFR) 
therapy and (iv) multigene expression analysis (Oncotype Dx) to identify and spare 
non-responders the debilitating effects of particular chemotherapy interventions.
Our findings indicate that Oncotype Dx is cost-effective in high income settings 
within specific price points, by limiting treatment toxicity in CRC patients. DPYD status 
testing may also be cost effective in certain settings to avoid specific 5-FU toxicities 
post treatment. In contrast, current research does not support UGT1A1 polymorphism 
status as a cost-effective guide to irinotecan dosing, while the health economic evidence 
to support testing of KRAS/NRAS mutational status and chemo/EGFR therapy choice 
was inconclusive, despite its widespread adoption in CRC treatment management. 
However, we also show that there is a paucity of high-quality cost-effectiveness studies 
to support clinical application of precision medicine approaches in CRC.
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INTRODUCTION
Globally, colorectal cancer (CRC) is the second 
most common cancer in women (~746,000 new cases 
annually), and third most common in men (~614,000 
new cases annually); and the annual number of deaths 
approaches 700,000 [1]. CONCORD-3 [2] identified 
>5.9M CRC patients in 2014. In Europe, 447,000 new 
cases and 215,000 deaths are reported each year [3]. 
The economic cost of CRC in the Europe (EU) alone is 
over €22 billion per year in healthcare costs [Henderson 
et al, manuscript in preparation]. Within the UK, in 2015, 
                       Review
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almost 42,000 new cases of CRC were documented [4], 
with over 16,000 CRC deaths [5] and a cost of €2.3 billion 
(Henderson et al Manuscript in Preparation).
An increased understanding of the biology 
underpinning malignancy has indicated that many cancers, 
including CRC, are composed of a number of different 
molecular disease subtypes, which may show differing 
responses to therapeutic intervention. Identification 
of appropriate prognostic and predictive molecular 
biomarkers (MBMs), which can distinguish between 
these different subtypes, can assist clinical decision-
making, such that patients receive the most appropriate 
treatment based on their molecular profile. This stratified 
or precision medicine approach has the potential to 
contribute to enhanced therapeutic efficacy, while 
minimising treatment-related toxicity. 
To identify MBMs of the required clinical utility, 
e.g. diagnostic (identifying cancer subtype), predictive 
(determining likelihood of response to therapy), or 
prognostic (indicating course of disease), analytical 
platforms are becoming more sophisticated, incorporating 
technologies such as gene expression profiling and next-
generation sequencing. Interpretation of data generated 
from these platforms is performed using different 
bioinformatics approaches, adding to overall complexity 
[6]. The National Institute of Health (NIH) Genetic 
Testing Registry currently lists 30 MBM tests for CRC 
[7]. These are employed for a variety of purposes, 
including: diagnosis, mutation detection/confirmation, 
pre-symptomatic indications, predictive testing, prognostic 
determination, drug response evaluation, and treatment 
management.
For researchers and clinicians to embrace a MBM 
test, it must demonstrate analytical validity, clinical 
validity, and, most importantly, clinical utility [8]. 
These parameters should be established before a cost-
effectiveness analysis (CEA) is attempted. Phillips et al. 
[9] examined economic utility analyses of MBM tests 
in personalised/precision medicine and found that while 
nearly three quarters of the tests (72%) were associated 
with better outcomes, these outcomes were in many 
cases associated with higher costs. However, almost 
half of the MBM tests fell below a threshold of £35,000 
(€40,000 or US$50,000) per quality-adjusted-life-year 
(QALY), and 20% of the tests showed evidence of cost-
savings. A recent paper has identified several MBMs for 
CRC with prognostic (BRAF and DNA mismatch repair 
status) and predictive (KRAS and NRAS) utility [10]. 
Sepulveda et al. [10] also note that mismatch repair status 
indicates a predictive benefit in patients assessed for 
immunotherapeutic intervention.
Decision makers such as healthcare payers need to 
know both the financial and the health-related implications 
of introducing MBM testing. Limited information on the 
contribution to patient outcomes and societal benefit is 
often cited as the basis for lack of reimbursement for a 
particular MBM test [11]. Therefore, the rationale for the 
systematic review reported here was to compile the body 
of cost effectiveness evidence generated for MBM testing 
for CRC in high income health systems, to determine if 
certain MBM tests can help deliver value-based care. 
MATERIALS AND METHODS
Following Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) guidelines, 
this review is registered with PROSPERO (registration 
number: CRD42016038046) and the findings conform to 
that registration [12].
Scoping search
5-Fluorouracil (5-FU) has been the backbone of 
chemotherapeutic regimens for CRC since the late 1950s. 
As part of our initial scoping search, we identified thirteen 
other drugs that have been approved by the Food and Drug 
Administration (FDA) for treatment of CRC since 1996 
(see Supplementary Table 1). 
Search strategy
Our research question, formulated using the 
PICOS framework (population, intervention, comparator, 
outcome, study design) was “What is the cost-effectiveness 
of using a MBM test for predicting response to therapy in 
CRC?”. PICOS was employed to develop a search limited 
to studies that performed economic evaluation of patients 
diagnosed with CRC, who were subsequently stratified for 
treatment selection by the result of a MBM test. Initially, 
a scoping search was performed to identify keywords and 
MeSH headings. Articles were identified by systematic 
literature search if they were published between 1 January 
2006 and 31 December 2016. We searched MEDLINE, 
EMBASE, Cochrane Library, SCOPUS, Web of Science, 
Econlit and SCHARR. Meeting presentations were 
also searched for the same time period in the American 
Society of Clinical Oncology (ASCO) and International 
Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) websites. Boolean operators were used to set 
up weekly searches of the above databases throughout 
the preparation of the review to keep it current, with 
the addition of Google Scholar alert searches at least 3 
times per week until the end of 2018. All bibliographic 
references retrieved via the searches were exported to 
reference management software, and duplicates were 
removed before the study selection step.
Study selection
Articles were screened for eligibility based on the 
following criteria (Table 1):
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Titles and abstracts of all articles were reviewed 
for eligibility and only accepted if the above criteria were 
met. Four reviewers (RH, DF, MC and ML) independently 
evaluated the full text of potentially eligible articles 
to determine whether to include these articles in this 
review. A lack of consensus over eligibility was resolved 
between the four reviewers. If doubts remained about 
the suitability of the study (such as academic posters 
which lack full peer review), we took the conservative 
approach of including these studies, so as to avoid missing 
potentially informative studies, while noting that they had 
not undergone full peer review.
The integrity of each study was assessed according to 
a checklist developed by the ISPOR Consolidated Health 
Economic Evaluations Reporting Standards (CHEERS) 
Task Force Report [13]. This underpinned the development 
of a quality rating for each study, thus allowing rigorous 
evaluation of the strength of the data provided. Quality 
ratings were assigned in five categories: Excellent 
() if a study met 23-out-of 24 CHEERS criteria; 
good () if 21-22 criteria were met; studies meeting 
19–20 criteria were graded as medium (). If only 17–
18 criteria were met, the study was graded as low (), 
while studies with 16 criteria or less being met were graded 
as poor ().
Mathematical formulae employed
In cases where more than one therapy were modelled, 
the reported ICER might not be compared to the base case, 
e.g. best supportive care (BSC). In these instances, we 
calculated the ICER based on reported costings and QALYs 
for the MBM test using the following formula:
ICER = 
ΔCosts
ΔQALYs
Where LYGs were reported, but not QALYs, and no 
health utility was reported then:
QALYs = LYGs × 0.8
The baseline health utility score of 0.8 was 
calculated from studies identified in our systematic 
review, which ranged from 0.71 to 0.87 for progression-
free survival in CRC patients, which conforms with a 
published systematic review of health utility values for 
CRC [14]. Conversely, where QALYs were reported but 
not LYGs, and no health utility was reported then:
LYGs = 
QALYs
0.8
RESULTS
Scoping results
For each therapeutic intervention indicated, we 
listed the dates of FDA, European Medicines Agency, 
and National Institute for Health and Care Excellence 
(NICE) approval. We have identified the annual costs 
for each of these therapies, adjusted to 2016 £GBP and 
Euros using the CCEMG (Campbell and Cochrane 
Economics Methods Group) - EPPI (Evidence for Policy 
and Practice Information) - Centre Cost Converter [15]. 
We have also listed putative MBMs for each therapeutic 
intervention, where applicable, and noted whether each 
MBM was predictive of therapy, or prognostic of risk (see 
Supplementary Table 1).
Costs listed in Supplementary Table 1 are drug 
acquisition costs and do not include costs of outpatient 
visits, hospitalisation, treatment of side effects, etc. 
A potential benefit of targeted approaches using 
biological-based therapy is the avoidance or lessening 
of adverse effects; e.g. adverse effects resulting from 
EGFR-targeted therapy are relatively mild (e.g. skin 
rash) [16] in comparison to those observed with 5-FU 
(myelosuppression and gastrointestinal toxicity) [17]. It 
Table 1: Screening criteria and study design for systematic review
1 Patients: Diagnosed with CRC, not limited by age, gender, staging, or type of treatment intervention.
2 Intervention MBMs including: Single or multi-gene tests (Cobas, Snapshot, Therascreen, High Resolution 
Melting Assay (HRMA), Sanger sequencing, pyrosequencing, next-generation sequencing, 
multigene assays, mutational analysis); gene expression profiling (Oncotype DX, Coloprint); 
protein based tests [immunohistochemistry (IHC)]. All other tests were excluded.
3 Comparator No MBM test.
4 Outcomes: The health economic indicator incremental cost-effectiveness ratio (ICER) was investigated, as it 
relates to cost per QALY and cost per life year gained (LYG).
5 Study design: Screening for economic analyses based on models (which draw data from trials, resource use 
and health utility in a disaggregated form) or trials (which prospectively include all the required 
data). These included CEA, cost-benefit analysis (CBA), cost-minimization analysis (CMA) and 
cost-utility analysis (CUA). Budget-impact, reviews, letters and editorials were excluded from 
the systematic review, but were retained for reference.
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can be difficult to compare targeted therapy directly to 
chemotherapy as in many instances both are administered 
in combination, but where targeted therapy is employed, 
there is potential for a consequential therapeutic benefit in 
advanced CRC [18]. The MBMs listed in Supplementary 
Table 1 represent the biomarkers most frequently 
employed for the indicated therapy.
Study selection
The Study Selection Workflow is outlined in 
Figure 1. Our initial database search and other electronic 
searches (ASCO, ISPOR) followed the search strategy 
set out in the Methods section and identified 6,706 
records. We developed a text-mining algorithm based on 
health economic filters, as there was a paucity of these 
represented in the identified records. Consequently, 
6,560 records were excluded, and the remaining 146 
records were imported into reference management 
software, where duplicate records (n = 25) were 
removed. A total of 121 articles were then screened 
for eligibility. After full text examination, 25 articles 
were excluded as these reported CEAs that related to 
screening of families for hereditary CRC, which is not 
relevant to the research question being posed in this 
systematic review. A further 16 articles were either 
reviews or systematic reviews which were retained 
for reference, and 5 articles did not mention the terms 
LYG, QALY, or ICER. A total of 12 other articles did 
not include CBAs, CEAs, CMAs, or CUAs and 12 
articles focused on CRC therapy alone, not taking into 
account the use of MBM tests to help guide therapy. 
On further examination, 7 articles were identified as 
duplicate studies (earlier abstract reports of the same 
study or versions of the same study published in other 
languages), a further 7 were abstracts without sufficient 
information, 3 articles involved a mixed population of 
cancer types which either included data already captured 
or aggregated data from which CRC-specific data could 
not be extracted, 1 study was an incomplete trial with 
insufficient data, and 5 were letters with insufficient 
detail for inclusion. In total, 14 eligible studies remained 
which involved economic evaluation of a MBM test for 
guiding therapeutic intervention in CRC.
Data extraction
We extracted empirical and methodological data 
and imported the data into Microsoft Excel. Extracted 
features included: author, year, country of study, CRC 
stage/metastases/not described, therapy, biomarker utilised, 
LYG, QALY, and ICER employed (Table 2A–2C). We also 
extracted Author, perspective (healthcare payer, health 
insurance or hospital), modelling approach, time horizon 
(duration of therapy), discounting applied, health utility 
questionnaire, setting and location, comparisons, scenario 
analysis, deterministic sensitivity analysis (DSA), and 
probabilistic sensitivity analysis (PSA) to prepare Table 
3A–3C. If there was insufficient data (e.g. abstract reports 
from conferences), we emailed the original authors for 
further details.
A quality rating for each study was determined (see 
Methods) which allowed us to assign a level of confidence 
in the strength of evidence for each study. The quality 
assessment was performed by one reviewer, checked by 
a second reviewer and any disagreement was resolved by 
the third and fourth reviewers.
Figure 1: PRISMA flow diagram, showing the flow of identified records through screening, assessment for eligibility, 
and inclusion.
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Table 2A: Study characteristics, outcomes, and quality assessment of DPYD and UGT1A1 studies 
Author Year Countrya CRC type Therapy Biomarker(Methodology) LYG QALY ICER (£&€/QALY) Quality rating
Traoré 
et al. [21] 2012 France ND 5-FU
DPYD (genotyping/
phenotyping) No No
£2,795b (€3,175) 
Butzke et 
al. [23] 2015 Germany Metastatic FOLFIRI UGT1A1 (PCR) < 1 day <1 day £60,566,870 (€68,810,212) 
Gold et al. 
[24] 2009 USA Metastatic FOLFIRI UGT1A1 (PCR) < 1 day <1 day Dominated
d 
Obradovic 
et al. [25] 2008 USA Metastatic Irinotecan UGT1A1 (PCR) 0.02233 0.01786
c £1,318,354 (€1,497,786) 
Pichereau 
et al. [26] 2010 France Metastatic FOLFIRI UGT1A1 (PCR) No No £966
e (€1,097) 
Abbreviations: 5-FU, Fluorouracil; FOLFIRI-FOL, Folinic acid (leucovorin); F - Fluorouracil (5-FU); IRI, Irinotecan (Campto); FOLFOX-FOL, Folinic acid (leucovorin); F, 
Fluorouracil (5-FU); OX, Oxaliplatin (Eloxatin); ICER, incremental cost-effectiveness ratio; LYG, life year gained; ND, not described; PCR, polymerase chain reaction; QALY, 
quality-adjusted-life-year. 
aCountry evaluated. 
bLYG or QALY not stated. 
cFigures in bold calculated from a 0.8 health utility score. 
dDominated; other treatments are less costly and more effective 
eICER not based on £/QALY, but as the cost to avoid one febrile neutropenia event per 1000 patients. 
Table 2B: Study characteristics, outcomes, and quality assessment of BRAF and RAS (KRAS and NRAS) studies
Author Year Countrya CRC Type Therapy
Biomarker
(Methodology) LYG QALY ICER (£&€/QALY)
Quality 
rating
Behl et al. [31] 2012 USA Metastatic Cmab
Cmab
KRAS
KRAS & BRAF 
(PCR clamping and 
melting curve method)
0.0344
0.0340
0.0275
0.0272
£409,877 (€465,633)
£396,507(€450,473)

Blank et al. [32] 2011 Switzerland Metastatic Cmab
Cmab
KRAS
KRAS & BRAF 
(PCR, then sequencing)
0.6163
0.6138
0.4930
0.4910
£49,735 (€56,505)
£48,999 (€55,688)

Carlson JJ [33] 2010 USA Metastatic Cmab KRAS  
(PCR, then sequencing)
0.1500 0.1100 £204,766 (€232.635) 
Harty, Jarret, and 
Jofre-Bonet [34]
2015 UK Metastatic Cmab
Cmab
KRAS
RAS 
(PCR clamping and 
melting curve method)
0.2900
0.4500
0.2200
0.2400
£73,003 (€82,939)
£44,767 (€50.860)

Health Quality 
Ontario. [35]
2010 Canada Metastatic Cmab 
Pmab
Cmab + 
Irinotecan 
KRAS (Therascreen) 0.3951
0.2903
0.6591
0.3082
0.2264
0.5141
£35,095 (€40,440)
£30,607 (€34,773)
£27,351 (€31,074)

Shiroiwa et al. [36] 2010 Japan Metastatic Cmab KRAS  
(PCR, then sequencing)
0.1800 0.1300 £109,452 (€124,349) 
Vijayaraghavan  
et al. [37]
2011 USA & 
Germany
Metastatic Cmab 
Pmab
Cmab + 
Irinotecan 
KRAS
(PCR, then sequencing)
0.3804
0.3511
0.4665
0.3043
0.2809
0.3732
£58,210 (€66,133)
£54,138 (€61,506)
£72,714 (€82,611)

Westwood et al. [38] 2014 UK Metastatic Cmab KRAS (Therascreen) 0.2250 0.1800 £17,616 (€20,013) 
Abbreviations: Cmab, cetuximab; EGFR, epidermal growth factor receptor; Pmab, panitumumab.
aCountry evaluated.
bFigures in bold calculated from a 0.8 health utility score.
Table 2C: Study characteristics, outcomes, and quality assessment of oncotype DX studies 
Author Year Countrya CRC type Therapy Biomarker(methodology) LYG QALY ICER (£/QALY)
Quality 
rating
Alberts et al. 
[39]
2014 USA Stage II, T3, 
MMR-P
Fluoro-pyrimidine 
and FOLFOX
Oncotype DX (12-gene assay 
RT-PCR)
0.1425b 0.114 £21,052c(€23,917) 
Abbreviations: MMR-P, mismatch repair proficient; RT-PCR, reverse transcriptase PCR.
aCountry evaluated.
bFigures in bold calculated from a 0.8 health utility score.
cBased on a converted US list price of £2,400 for the Oncotype DX colon test.
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Data synthesis
Data capture and quality analysis for each study 
of cost-effectiveness were represented in Tables 2 and 
3 and as a narrative summary. Where appropriate, costs 
were adjusted for year, inflation, and local currency using 
the CCEMG - EPPI - Centre Cost Converter [15]. The 
modelling techniques used in the different studies were 
Table 3A: Methodological characteristics of DPYD and UGT1A1 studies
Author Perspective Modelling approach
Time 
horizon Discount
Health 
utility Setting
WTP 
threshold
Scenario 
analysis DSA PSA
Traoré 
et al. [21]
ND Decision 
analytic 
-Markov
2 cycles of 
chemo-
therapy
No No ND ND No No Yes
Butzke  
et al. [23]
German statutory 
insurance
Decision 
analytic 
-Markov
Lifetime 3% EQ-5D German 
population
€50,000 No Yes Yes
Gold et al. 
[24]
Medicare payer Decision 
analytic
No 3% Yes ND US$100,000 No Yes Yes
Obradovic  
et al. [25]
US health-care 
payer
Decision 
analytic
No No No ND US$100,000 No No Yes
Pichereau 
 et al. [26]
French hospital Decision 
analytic
No No No Medical 
care 
practice in 
France
ND No No Yes
Abbreviations: DSA, Deterministic Sensitivity Analysis; EQ-5D, EuroQol five dimensions’ questionnaire; PSA, Probabilistic Sensitivity Analysis; WTP, 
Willingness to Pay.
Table 3B: Methodological characteristics of BRAF and RAS (KRAS and NRAS) studies 
Author Perspective Modelling approach
Time 
horizon Discount
Health 
utility Setting
WTP 
threshold in 
LCU
Scenario 
analysis DSA PSA
Behl et al. [31] ND Decision analytic 
-Markov
2½ years 3% No ND US$100,000 No No Yes
Blank et al. [32] Swiss health 
system
Decision analytic 
-Markov
Lifetime 3% HUI3 ND €40,000 Yes Yes Yes
Carlson JJ. [33] ND Decision analytic 
-Markov
No 3% Yes ND US$0 to 
$300,000 
CEAC
No Yes No
Harty, Jarret, and 
Jofre-Bonet [34]
NHS Decision analytic 
-Markov
10 years No No ND £50,000 No Yes No
Health Quality 
Ontario. [35]
Ontario Ministry 
of Health and 
Long-Term Care
Decision analytic 
-Markov
Lifetime 5% QLQ-C30 Ontario CAD$50,000 No No Yes
Shiroiwa et al. [36] Japanese 
healthcare payer
Decision analytic 
-Markov
2½ years 3% HUI3 ND ¥5 to 6 million Yes Yes Yes
Vijayaraghavan  
et al. [37]
US & German 
healthcare payer
Decision analytic 
-Markov
Lifetime No No ND ND No Yes No
Westwood et al. 
[38]
NHS Decision analytic 
-Markov
23 years 3.5% EQ-5D England 
and Wales
ND No Yes No
Abbreviations: HUI3, Health Utility Index Mark 3; QLQ-C30, Quality-of-Life Questionnaire; CEAC, Cost-Effective Acceptability Curve; LCU, Local Currency Units; ND, Not 
described; NHS, National Health System.
aCountry evaluated.
Table 3C: Methodological characteristics of oncotype DX study
Author Perspective Modelling 
approach
Time 
horizon
Discount Health 
utility
Setting WTP threshold 
in LCU
Scenario 
analysis
DSA PSA
Alberts et al. [39] US third party 
payer
Decision analytic-
Markov
5 years 3% Yes Physicians in 
the MCCRC
US$50,000 Yes Yes yes
Abbreviations: LCU, local currency units; MCCRC, Mayo Clinic Cancer Rese arch Consortium.
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compared, and their robustness analysed. Finally, the 
quality of our systematic review itself was checked using 
two instruments, AMSTAR (Assessing the Methodological 
Quality of Systematic Reviews) [19] and MECIR 
(Methodological Expectations of Cochrane Intervention 
Reviews) [20].
Study characteristics
Tables 2A–2C outline the characteristics, resulting 
outcomes, and quality assessment of each study.
DPYD
Table 2A lists one study that evaluated DPYD gene 
status in relation to 5-FU toxicity [21]. 5-FU is converted 
to dihydrofluorouracil by the enzyme dihydropyrimidine 
dehydrogenase (DPD), expressed by the DPYD gene. 
More than 80% of administered 5-FU is detoxified in the 
liver by DPD metabolism [22]. 
UGT1A1
Table 2A lists four economic evaluations involving 
UGT1A1 testing to guide irinotecan dosing [23–26]. The 
chemotherapy drug irinotecan is converted principally 
in the liver by carboxylesterase to SN-38, the active 
anticancer agent which inhibits topoisomerase I [27]. 
KRAS/BRAF
Table 2B groups the genes RAS (KRAS and NRAS) 
and BRAF, (which are expressed as signalling molecules 
in the mitogen-activated protein kinase pathway 
(MAPK)) in relation to their use as prognostic/predictive 
MBMs in CRC. Tumours harbouring mutated forms 
of these genes are resistant to anti-epidermal growth 
factor receptor (EGFR) therapy [28]. RAS (KRAS and 
NRAS) mutations occur in 53% of CRC patients [29] 
and BRAF mutations in approximately 10% [30]. Most 
of the economic analyses are performed in the context 
of genotyping the patient for RAS mutational status 
(KRAS and NRAS) before either treatment with an EGFR 
monoclonal antibody or chemotherapy treatment. 
The majority of health economic evaluations 
(N = 8) involved RAS and BRAF testing prior to CRC 
treatment with cetuximab and panitumumab [31–38].
Oncotype DX
Table 2C records data associated with the use of a 
12-gene assay (Oncotype DX colon cancer) as a predictor 
of the risk of CRC recurrence [39], thus informing 
the choice of fluoropyrimidine and FOLFOX (FOL - 
Folinic acid (leucovorin); F - Fluorouracil (5-FU); OX - 
Oxaliplatin (Eloxatin)) treatment options. 
Health outcomes for each MBM
DPYD
The ICER generated for DPYD in Table 2A was 
£2,795 (€3,175) based on neither LYG nor QALY metrics, 
but on the prevalence of toxicity episodes from 5-FU, that 
is, cost per toxicity [21]. 
UGT1A1 
The CEAs for UGT1A1 testing were used to guide 
irinotecan dosing (Table 2A). The ICERs generated here 
were all above the NICE threshold of £30,000 (€34,083), 
with the exception of one study [26], but in this case the 
ICER was based on numbers of febrile neutropenic events 
avoided, and not on LYGs or QALYs. Table 2A lists the 
most significant QALYs generated by these CEAs as being 
only 6.5 quality-adjusted life days (QALDs) [25]. The two 
medium and good quality UGT1A1/irinotecan CEA studies 
generated even smaller QALYs, at an average increment that 
is calculated as less than 2 hours [23] and a decrement of 
less than two hours [24], which in turn led to the generation 
of very high ICERs. Additionally, although the Obradovic 
et al. [25] study indicates 6.5 QALDs, we agree with the 
report from the Centre for Reviews and Dissemination at the 
University of York [40], that these results should be treated 
with caution as the protocol was insufficient in detail to 
allow a quality assessment to be performed
KRAS/BRAF 
The results in Table 2B indicated that the Health 
Quality Ontario (HQO) study [35] and the Westwood et 
al. study [38] both yielded ICER values that fell below 
the NICE threshold. HQO performed three studies, one 
of which produced an ICER of £27,351 (€31,074), and 
187 QALDs using KRAS testing prior to cetuximab plus 
irinotecan treatment, compared to best supportive care 
(BSC – palliative care). The second HQO CEA for KRAS 
screening prior to panitumumab treatment (compared to 
BSC) came very close to the NICE threshold with an ICER 
of £30,607 (€34,773) and over 82 QALDs. The third HQA 
CEA for KRAS screening before cetuximab monotherapy 
(compared to BSC) generated an ICER above NICE’s 
threshold at £35,095 (€40,440) with 112 QALDs; however, 
these 3 studies were rated as medium-quality studies, as 
the report did not outline a structured summary, describe 
its analytical methods, or mention funding sources and 
conflicts of interest. The CEA from the Westwood et al. 
[38] study resulted in an ICER of £17,616 (€20,013) and 66 
QALDs and was rated a good quality study in respect to the 
CHEERS criteria. The other two good quality studies, by 
Shiroiwa et al. [36] and Blank et al. [32], produced ICERs 
of £109,452 (€124,349) (over 45 QALDs for KRAS testing 
prior to cetuximab treatment) and £48,999 (€55,668) (over 
179 QALDs for combined KRAS and BRAF screening 
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prior to cetuximab treatment), respectively. These ICERS 
were above the NICE threshold of £30,000 (€34,083). The 
remaining studies were of medium to poor quality, missing 
important details when applying the CHEERS checklist.
Oncotype DX 
In Table 2C, the Oncotype DX test [39] for 
predicting CRC recurrence had a QALY of 0.114, just over 
41 QALDs, and the ICER of £21,052 (€23,917) was below 
NICE’s threshold of £30,000 (€34,083). 
Type of economic evaluation undertaken for 
each MBM
All studies undertaken were CEAs.
DPYD
Incremental costs relating to toxicities following 
5-FU administration are indicated in Table 2A [21]. 
UGT1A1
In the CEAs detailing UGT1A1 genotyping to guide 
irinotecan dosing, one study [25] reported ICER per LYG, 
two studies [23, 24] reported ICERs per QALY, while 
Pichereau et al. [26] based their ICER on cost to avoid 1 
case of febrile neutropenia per 1000 patients.
RAS/BRAF
In Table 2B, 6 of the CEAs involving RAS (KRAS 
and NRAS) and BRAF testing utilised QALYs to calculate 
their ICERs. The exceptions are Behl et al. [31] and 
Vijayaraghavan et al, [37] which employed LYGs.
Oncotype DX 
In Table 2C, Alberts et al. [39] calculated the QALY 
for the Oncotype DX assay. 
Healthcare perspective, decision model, and time 
horizon for each MBM evaluated
Tables 3A–3C outline the methods and models used 
in the included studies. 
DPYD
Traoré et al. [21] did not describe the healthcare 
perspective for their DPYD testing CEA. A decision 
analytic approach in combination with a Markov model 
was employed to assess resource use and health outcomes. 
The time horizon was 2 cycles of chemotherapy.
UGT1A1
The healthcare perspective for CEAs for UGT1A1 
genotyping to guide irinotecan dosing was described 
from the perspective of the healthcare payer in 3 studies 
[23–25], whereas Pichereau et al. [26] focussed on the 
perspective of the hospital (Table 3A). While Butzke 
et al. [23] employed a decision analytic approach in 
combination with a Markov model and a lifetime time 
horizon, the remaining 3 studies solely employed a 
decision tree to model treatment strategies [24–26], with 
no specified time horizon (Table 3A).
RAS/BRAF
CEA analysis for RAS (KRAS and NRAS) and BRAF 
BM testing to inform anti-EGFR therapy was modelled 
in 6 of 8 studies from the healthcare payer perspective 
(Table 2B). All employed a decision analytic approach 
in combination with a Markov model. Seven (7) of 8 
employed a time horizon which varied from 2.5 years 
to a lifetime horizon (Table 3B), the sole exception 
being Carlson et al. [33], which we ranked as a poor-
quality study (missing information included; a structured 
summary, setting and location, study perspective, time 
horizon, assumptions made, funding, and conflicts of 
interest).
Oncotype DX
The perspective of the healthcare payer was 
employed for the Oncotype DX study (Table 3C). A 
decision analytic approach in combination with a Markov 
model was employed with a 5-year time horizon (Table 
3C).
Discounting and health utility for each MBM 
evaluated 
Discounting should reflect each country’s borrowing 
rate, but in health economic analysis the discount rate is 
usually set by the modellers at between 0% and 7%, with 
3% and 5% being the most frequently quoted figures. 
However, it has previously been reported that almost a 
third of economic evaluations in healthcare do not use a 
discount rate [41]. Our findings were similar, with 5 of 14 
(36%) studies not using a discount rate.
DPYD
A discount rate was not used. No health utility 
questionnaire was employed.
UGT1A1
Two (2) of 4 UGT1A1 studies [23, 24] employed a 
discount rate of 3%. These studies also employed a health 
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utility questionnaire; EQ-5D was used by Butzke et al. 
[23] while Gold et al. [24] did not specify which health 
utility questionnaires they employed.
RAS/BRAF
Six (6) of 8 RAS/BRAF studies employed a discount 
rate, which ranged from 3-5%. Five (5) of 8 studies 
employed a health utility questionnaire; in 4 cases [32, 
35, 36, 38] the type of health utility questionnaire was 
indicated (Table 3B) 
Oncotype DX
The Oncotype DX study employed a discount rate of 
3% and used a health utility questionnaire, but the type of 
questionnaire was not specified (Table 3C).
In summary, only CEAs with a good or excellent 
rating [23, 32, 35, 36, 38] captured the healthcare 
perspective, decision model, time horizon, discounting, 
and health utility, the remaining studies were inconsistent, 
only capturing a number of these parameters. Only 4 
studies described a setting and/or location; Pichereau 
et al. [26] and Butzke et al. [23] for UGT1A1 testing, HQO 
[35] for KRAS testing and Alberts et al. [39] for Oncotype 
DX testing. Only Traoré et al’s DPYD study [21] used a 
single study; the remainder were synthesis based. None 
of the studies covered a reduction in productivity due to 
adverse effects, illness, or death.
Willingness to pay thresholds for each MBM 
evaluated
DPYD
A willingness to pay (WTP) threshold was not 
employed.
UGT1A1
Three (3) out of 4 studies reported WTP thresholds, 
which range from €50,000 in 2013 (£46,950 or €53,340 in 
2016) [23] to US$100,000 in 2006 (£81,606 or €92,713 in 
2016) [25, 26].
RAS/BRAF
Six (6) of 8 studies used a WTP threshold which 
ranged from a Canadian study [35] which set the 
threshold at CAD$50,000 (£32,019 or €36,377) to a 
US study [31] which set the threshold at US$100,000 
(£76,440 or €86,844). Carlson [33] constructed a cost-
effective acceptability curve (CEAC) with a WTP 
threshold between US$0 and US$300,000 (£0 or €0 
and £232,122 or €263,715) while Westwood et al. [38] 
utilised a CEAC with a WTP threshold up to £100,000 
(€111,159). Vijayaraghavan et al. [37] did not use a WTP 
threshold.  
Oncotype Dx
Alberts et al. [39] limited the WTP threshold to 
US$50,000 (£35,595 or €40,440) (Table 3C).
Sensitivity analyses for each MBM evaluated
Sensitivity analyses were performed to test the 
degree of uncertainty in health benefits and costs. 
DSA tested parameters such as clinical effects, disease 
progression, QALYs and costs one at a time, while the 
superior PSA tested these parameters in combination.
DPYD
Traoré et al. [21] conducted a PSA, but did not 
detail the findings in their report. 
UGT1A1
Gold et al. [24] and Butzke et al. [23] performed 
both DSA and PSA, whereas Obradovic et al. [25] and 
Pichereau et al. [26] only performed PSA. These analyses 
were employed to address the uncertainty surrounding 
the cost-effectiveness of irinotecan dosing based on the 
application of the UGT1A1 BM test.
RAS/BRAF
The PSA in the HQO paper [35] showed that for 
KRAS testing, cetuximab plus irinotecan was the most 
cost-effective therapy when compared to BSC. The DSA 
from Vijayaragharan et al. [37] indicated that the most 
sensitive parameter in the model was the percentage of 
KRAS WT patients in the population. The DSA used by 
Shiroiwa et al. [36] did not find parameter changes to 
have an effect on the results, whilst their PSA found KRAS 
testing to be 62% cost-effective at a WTP threshold of ¥20 
million (£196,010 or €222,688). The PSA from Westwood 
et al. [38] did not vary much from the base case, that is, all 
KRAS testing strategies were almost equal.
The scenario analysis performed by Blank et al. [31] 
described a minor impact on the ICER. Blank et al. [32] 
also noted KRAS and BRAF testing to be the dominant 
strategy at a WTP threshold of €10,000 to €40,000 
(£13,930 to £38,892), whilst at a WTP threshold greater 
than €40,000 (£38,892), KRAS testing was dominant. 
The tornado plot by Harty et al. [34] indicated that the 
duration in first line progression was most sensitive in the 
DSA. The DSA performed by Behl et al. [31] revealed 
the model to be sensitive to conversion of chemotherapy 
costs, cetuximab therapy, and the cost of surgery. Carlson’s 
[33] DSA detailed via a tornado plot how BSC was most 
sensitive to difference in QALYs.
Most studies which used a PSA approach [32, 35, 
36, 38] came to the same conclusion, namely that it is 
most cost-effective to use a MBM to test for treatment 
selection before therapy.
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Oncotype Dx
The DSA and PSA indicated that QALYs were 
sensitive to: (1) benefit of fluoropyrimidine monotherapy over 
surgery alone, (2) benefit of FOLFOX over fluoropyrimidine 
monotherapy, and (3) time preference discount rate. 
Cost comparison of anti-EGFR therapy versus 
chemotherapy or BSC
Supplementary Table 2 lists the four studies which 
included costs of treatment with anti-EGFR therapy 
compared to chemotherapy (or BSC). For patients with 
a mutation, health economic analysis indicates that an 
average of £88,147 (€100,144) per year is saved per patient, 
due to avoidance of cetuximab therapy based on the KRAS/
BRAF test result. For panitumumab therapy, the average 
cost saving is £41,159 (€46,761) per patient per year.
Comparison of ICERs, No MBM versus MBM
Supplementary Table 3A illustrates how the use 
of MBMs can help increase the cost-effectiveness of 
treatment, with the exception of UGT1A1, which is used 
to guide the reduction of irinotecan dosing.
As shown in Supplementary Table 3B, the use of 
the KRAS MBM reduced the ICER for cetuximab from 
£142,515 (€161,912) to £109,452 (€124,349) in the 
Shiroiwa et al. study [36] and for panitumumab from 
£48,118 (€54,667) to £30,607 (€34,773) in the HQO study 
[35]. However, although these MBMs improved the cost-
effectiveness of these therapies, this did not lead to the 
intervention achieving an ICER below the NICE threshold 
in either case, although the HQO study was within the 
margin of error 
KRAS and BRAF guided chemotherapy costs 
with corresponding QALYs and ICERs
From reported costs and positive effects (e.g. changes 
in progression-free survival) in three studies (32, 33, 35), 
we were able to generate ICERs (Supplementary Table 4) 
for chemotherapy if the patient population had KRAS (or 
BRAF) mutations. Two studies [32, 34] resulted in ICERs 
below the NICE threshold, at £8,742 (€9,932) and £23,072 
(€26,212) respectively. However, the third study by Behl et 
al. [31] while breaching the NICE threshold with an ICER 
of £49,005 (€55,675), was still under the WTP threshold of 
US$100,000 (£76,440 or €86,844).
Genetic heterogeneity within populations and its 
effect on CEA
It is important to note that the ICERs for the MBMs 
evaluated in this systematic review are susceptible to 
the frequency of mutations in the general population. 
The UGT1A1*28 polymorphism occurs with higher 
prevalence in the African (42–56%) and Caucasian 
(26–31%) populations, than in Asian populations 
(9–16%). Consequently, the use of this biomarker leads to 
a ten-fold increase in Africans LYGs compared to Asian 
LYGs, when used to guide irinotecan treatment. However, 
even with this increase in LYG, this MBM is still not 
cost-effective [25]. 
DISCUSSION
The economic impact of MBM testing to guide 
therapy in CRC depends upon the cost of the therapeutic 
intervention and the price of the test, balanced against 
the clinical impact of the intervention and the degree of 
toxicity to the patient. So, if the net savings and QALYs are 
within a specific country’s WTP threshold, the value-based 
reimbursement of the MBM may help justify a stratified/
precision medicine approach to cancer treatment [42].
DPYD genotyping to guide 5-FU and 
capecitabine treatment
Deenen et al. [43], in a safety and cost analysis 
of DPYD*2A screening prior to treatment, showed that 
genotyping marginally improves patient outcomes, and 
is also cost saving (€2,772 screening versus €2,817 non-
screening). The CEA by Traoré et al. [21] and Deenan et 
al.’s study demonstrates that establishing DPYD screening 
in clinical practice in advance of 5-FU or capecitabine 
treatment may be cost-effective. On the evidence that we 
have presented and evaluated in this systematic review, 
DPYD screening is not only cost saving, but also spares 
patients the associated toxicities, although the overall net 
monetary benefit may be minimal.
UGT1A1 genotyping to guide irinotecan 
treatment
Three of the irinotecan studies [23–25] identified in 
our analysis suggest that prior testing for UGT1A1 may be 
cost saving, but our systematic review is inconclusive as 
to whether testing improves patient outcomes, with both 
positive [23] and negative [24] QALYs being reported. 
Goldstein et al. [44] stated that they cannot recommend 
UGT1A1 genotyping to guide irinotecan dosing, and that 
any dose reduction should be based on clinical parameters, 
rather than UGT1A1 status.
Lu et al. [45] attempted a different approach by 
escalating the dose in UGT1A1*1 homozygotes and 
UGT1A1*28 heterozygotes, with positive therapeutic 
results without the development of adverse effects; a 
RCT of this approach is ongoing [46]. As the optimum 
dosing of irinotecan based on UGT1A1 status has yet to 
be defined [47], UGT1A1 genotyping to guide irinotecan 
dosing will most likely need to be revisited following 
the availability of results from RCTs such as the one 
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highlighted above in order to determine its efficacy and 
cost-effectiveness.
RAS (KRAS and NRAS) and BRAF genotyping 
to guide treatment
Testing of patients with RAS (KRAS and NRAS) 
and BRAF mutations before anti-EGFR or chemotherapy 
administration has informed clinical decision making in 
CRC. Of the articles we identified, both the Canadian study 
by the HQO [35] and the UK study by Westwood et al. 
[38] generate ICERs below the NICE threshold for KRAS 
WT guided therapy compared to BSC and chemotherapy 
respectively. However, where RAS (and BRAF) testing were 
used to select chemotherapy for patients with the mutated 
form of these genes [32, 34], ICERs were generated below 
NICE’s WTP threshold, while the study by Behl et al. [31] 
resulted in an ICER below the WTP threshold for the USA. 
The remaining studies did not report enough information 
to calculate an ICER for MBM-guided chemotherapy. 
At present, NICE does not recommend cetuximab as a 
monotherapy [48] but recommends cetuximab if used 
in combination with either FOLFOX or FOLFIRI (FOL 
- Folinic acid (leucovorin); F - Fluorouracil (5-FU); IRI 
- Irinotecan (Camptosar))  [49]. From the eight studies 
identified for RAS family and BRAF mutation testing, the 
results overall were inconclusive as to whether precision 
medicine strategies are cost-effective when selecting CRC 
patients for anti-EGFR therapy. Although NICE’s WTP 
is set at £30,000, technology appraisals performed for 
end-of-life treatment guidance, have permitted costs to 
breach this threshold at an average of £49,000, implicitly 
suggesting a £50,000 WTP when end-of-life criteria are 
met. If this figure had been used as our benchmark in this 
metastatic CRC setting, then half of the studies would be 
classed as cost-effective [50]. Moreover, when costing and 
QALY data were reported for selection for chemotherapy 
treatment, RAS/BRAF testing did prove to be cost-effective. 
The cost savings can be significant. For example, given that 
more than one million CRC patients in Europe are expected 
to develop metastatic CRC [2, 51], with 53% harbouring 
RAS mutations, there is the potential to save £3 billion 
(€3.5 billion) over the lifetime of this patient cohort.
When MBM guided anti-EGFR therapy is compared 
to anti-EGFR therapy alone, there is a pronounced increase 
in the ICER values, but the QALYs produced are only 
marginally different. Thus, RAS (and BRAF) testing can 
only be cost-effective when selecting patients who should 
receive chemotherapy, but not those who receive EGFR 
therapy, based on the result of their molecular assay. 
Oncotype DX gene assay to guide 5-FU and 
FOLFOX treatment
The initial economic analysis of the Oncotype 
DX assay was generated by data from the National 
Comprehensive Cancer Network and concluded that the 
assay would improve patient outcomes (QALY = 0.035), 
and decrease costs by $3,000 for stage II, T3, proficient 
DNA mismatch repair CRC patients [52]. In the routine 
practice study by Alberts et al. [39], a larger QALY was 
generated because of the reduction in quality of life 
associated with adjuvant chemotherapy, and the lower 
cost savings ($991) due to oxaliplatin coming off patent. 
The ICER we calculated for the Oncotype DX assay was 
based on a $3,200 list price [53] and a QALY of 0.114. 
The applicability of the Oncotype DX Recurrence Score to 
other populations has been verified in African Americans 
[54], and although initially inconclusive in the Korean 
population [55], the larger SUNRISE study has established 
clinical validity in Asian populations [56]. An economic 
analysis of the Oncotype DX assay was deemed justifiable 
and is currently in progress in Israel [57]. Although the 
Alberts et al. CEA [39] was based on only 141 patients, 
the evidence, in combination with the prior CEA in 
another study [52], and favourable results from clinical 
trials [54–56] indicate that the Oncotype DX can spare 
patients unnecessary chemotherapy, is cost saving and 
falls below the NICE threshold.
Previous cost effectiveness analysis of precision 
medicine approaches in CRC 
There have been four previous systematic reviews 
on the economic analysis of MBM approaches in CRC 
in the personalised/precision medicine setting. The first 
was performed by Frank and Mittendorf in 2013 [58]. 
They identified 7 articles, 3 of referred to the use of 
the UGT1A1 MBM, while the remaining 4 investigated 
the KRAS MBM. We captured all 7 of these articles but 
excluded the study by Mittman et al. [59] because it did 
not utilise a MBM-based approach. Frank and Mittendorf 
concluded that the cost-effectiveness of UGT1A1 testing 
prior to irinotecan administration remains unresolved, 
whilst using KRAS genotyping to stratify patients before 
anti-EGFR treatment was cost-effective. The second 
systematic review, by Westwood et al. in 2014 [38], 
was a health technology assessment focusing on the 
cost-effectiveness of KRAS testing of CRC tumours. Its 
literature search found 5 articles, which we also identified, 
and the authors concluded that the ICER for KRAS 
mutation testing to guide anti-EGFR therapy was large. 
However, although they performed a CEA and found 
KRAS testing to be cost-effective, their results should be 
interpreted with caution as a number of assumptions were 
made in relation to resection rates, MBM test use, etc. The 
third paper by Guglielmo et al. [60] identified 5 KRAS 
studies, which we also uncovered in our literature search, 
but the study by Barone et al. [61] which they included did 
not meet our PICOS criteria as a CEA. Additionally, their 
review did not include the Canadian [35] or Japanese [36] 
studies we identified, because their search was limited to 
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2011 to 2016. Their findings for KRAS testing to guide 
anti-EGFR therapy were inconclusive. The fourth review 
by Seo and Cairns [62] identified 46 studies but only 12 
were relevant to our research question. We captured 11 of 
these studies, missing a poster by Niedersuess-Beke D. 
et al. [63]. Our findings correspond with Seo and Cairns, 
in that KRAS testing is always more cost-effective, even 
if this is not always the case for anti-EGFR therapies. 
However, we draw different conclusions from the data for 
the irinotecan studies, finding UGT1A1 testing not to be 
cost-effective.
We disagree with the Frank and Mittendorf 
systematic review on the lack of evidence to make a 
decision on the cost-effectiveness of UGT1A1, because 
our analysis indicates that there is enough evidence to 
support the assertion that the use of UGT1A1 genotyping 
to reduce irinotecan dosing is not cost-effective. Despite 
being able to select patients to receive chemotherapy, 
our findings suggest that there is insufficient evidence to 
indicate KRAS (and BRAF) testing is cost-effective, in the 
context of EGFR therapy.
It is evident that not all CRC patients currently 
benefit from precision medicine MBM-informed therapy, 
as is the case for the 53% of RAS mutant mCRC patients 
not eligible for anti-EGFR treatment [29]. The emerging 
field of molecular pathological epidemiology permits 
associations to be made between particular exposures 
(e.g. microorganisms, diet, lifestyle) and molecular 
pathological responses, identified through research on, for 
example, the interplay between the microbiome, tumour 
cells, and the immune system [64]. Patients harbouring 
PIK3CA mutated tumours benefit from exposure to 
aspirin, whereas PIK3CA wild-type patients do not [64]. 
Microsatellite instability high (MSI-H) tumours provoke 
a vigorous immunotherapeutic response; however, the 
presence of Fusobacterium nucleatum may counteract 
MSI-H positivity with associated immunosuppressive 
effects [64, 65]. The challenge in CEA is how to leverage 
multiple biomarkers such as RAS, BRAF, PIK3CA, 
MSI-H, and F.nucleatum positivity in a cost effective 
manner to precisely guide anti-EGFR therapy, aspirin 
therapy, and immunotherapy in mCRC. This challenge is 
becoming increasingly relevant as treatment algorithms 
incorporating multiple biomarkers become more common 
place and techniques such as whole genome sequencing 
enters clinical practice.
CONCLUSIONS
There is a paucity of high-quality CEAs that 
evaluate MBM in CRC. Unless CEA is incorporated 
prospectively into clinical trial design, economically 
unsubstantiated results can obscure the best available 
evidence, undermining both methodological approaches 
and resources. In summary, we found that the cost-
effectiveness of MBM approaches to guide CRC therapy 
is highly variable. The evidence from our review suggests 
that DPYD screening could be cost-effective in high-
income settings, if it is implemented before 5-FU therapy. 
Likewise, Oncotype DX assay is likely to be cost-
effective in identifying patients who will not benefit from 
chemotherapy. We were unable to find evidence to support 
UGT1A1 testing to guide irinotecan dosing. Perhaps more 
controversially, despite its adoption in many countries 
globally, we found that the cost-effectiveness data 
currently available to support anti-EGFR treatment based 
on RAS/BRAF mutational status is inconclusive. 
The evidence presented here reflects a need for a 
more rigorous methodological CEA-driven approach to be 
prospectively employed. There also needs to be greater 
transparency on prices used in CEA, so as to ensure the 
delivery of value-based care in a disease that kills nearly 
170,000 Europeans every year.
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